Ventilator associated pneumonia in the ICU: where has it gone?

Current Opinion in Pulmonary Medicine
Cristina Vazquez Guillamet, M H Kollef

Abstract

To highlight the clinical importance of ventilator-associated pneumonia (VAP) in an era of escalating antimicrobial resistance. VAP continues to be an important infection in the critically ill. The development of rapid microbiologic diagnostics and new antimicrobial agents offer opportunities for improved treatment strategies for VAP balancing the need to treat effectively in a timely manner and antimicrobial stewardship. Additionally, the new surveillance definitions for assessing the quality of care in critically ill patients (ventilator-associated events, ventilator-associated conditions, and infection-related ventilator-associated conditions) do not appear to be adequate surrogates for the identification of VAP. Clinicians caring for critically ill patients should be aware of the importance of correctly treating VAP. As new diagnostic technologies and antimicrobials become available for VAP, their incorporation into routine patient management should occur in a way that optimizes patient outcomes wherein minimizing further emergence of antimicrobial resistance.

References

Nov 20, 2002·Biomedical Engineering Online·Ritaban DuttaPascal Boilot
Dec 12, 2002·Chest·Jordi RelloUNKNOWN VAP Outcomes Scientific Advisory Group
Nov 20, 2003·JAMA : the Journal of the American Medical Association·Jean ChastreUNKNOWN PneumA Trial Group
Dec 25, 2004·Anesthesiology·C William Hanson, Erica R Thaler
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Dec 20, 2007·Critical Care Medicine·Daren K HeylandUNKNOWN Canadian Critical Care Trials Group
Apr 23, 2009·Critical Care Medicine·Jason A RobertsJeffrey Lipman
Jun 19, 2010·Chest·Nadia Z HaqueUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators
Sep 10, 2010·The New England Journal of Medicine·Catharina C BoehmeMark D Perkins
Sep 18, 2010·Diagnostic Microbiology and Infectious Disease·Antonio T FreireUNKNOWN 311 Study Group
Dec 15, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ethan RubinsteinUNKNOWN ATTAIN Study Group
Aug 20, 2011·American Journal of Respiratory and Critical Care Medicine·Maarten BekaertUNKNOWN Outcomerea Study Group
Jan 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard G WunderinkJean Chastre
Feb 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Marin H KollefFrank R Ernst
Apr 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paritosh PrasadCharles Natanson
Oct 18, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joel M DulhuntyJeffrey Lipman
Nov 9, 2012·Expert Review of Respiratory Medicine·Philip E GrgurichDonald E Craven
Nov 15, 2012·Critical Care : the Official Journal of the Critical Care Forum·Marin H KollefRebecca Redman
Mar 30, 2013·International Journal of Antimicrobial Agents·Paul C McGovernR Daniel Meyer
Oct 29, 2013·Critical Care Medicine·Shelley S MagillPamela Lipsett
Dec 3, 2013·Critical Care : the Official Journal of the Critical Care Forum·Clarence ChantJan O Friedrich
Jan 15, 2014·Antimicrobial Agents and Chemotherapy·G Ralph CoreySteven L Barriere
Feb 7, 2014·American Journal of Respiratory and Critical Care Medicine·Peter M C Klein KlouwenbergUNKNOWN MARS Consortium
Feb 20, 2014·Antimicrobial Agents and Chemotherapy·Anthony M CasapaoMichael J Rybak
Mar 13, 2014·Current Opinion in Pulmonary Medicine·Virve I EnneAlimuddin Zumla
Mar 13, 2014·Intensive Care Medicine·Lieuwe D J BosMarcus J Schultz
Apr 1, 2014·The Journal of Antimicrobial Chemotherapy·Pierre TattevinJean-Paul Stahl

❮ Previous
Next ❯

Citations

Feb 26, 2016·Annals of Clinical Microbiology and Antimicrobials·Tuna DemirdalSalih Atakan Nemli
Jul 2, 2015·American Journal of Respiratory and Critical Care Medicine·Marin H Kollef
Feb 9, 2017·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Hung-Jen TangChih-Cheng Lai
Dec 3, 2016·Journal of Medical Microbiology·Gürdal Yilmazİftihar Köksal
Nov 14, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jianfeng XieHaibo Qiu
Jan 20, 2016·Clinical Case Reports·Alexandre Franco MirandaAna Cristina Barreto Bezerra
Jul 9, 2017·Critical Care : the Official Journal of the Critical Care Forum·Yuetian YuYuan Gao

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
bronchoalveolar lavage

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.